You just read:

TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa

News provided by

TWi Biotechnology, Inc.

Oct 20, 2018, 09:41 ET